Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Constantin Lapa

Showing results (211-220 of 269) with videos related to

Pageof 27
Sort By:
Cancers|August 23, 2020
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical FeaturesXiang Zhou, Alexander Dierks, Olivia Kertels, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2022
Diverse PSMA expression in primary prostate cancer: reason for negative [<sup>68</sup>Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimensWojciech Cytawa, Stefan Kircher, Hubert Kübler, et al.
Annals of Nuclear Medicine|August 16, 2018
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implicationsRudolf A Werner, Ralph A Bundschuh, Lena Bundschuh, et al.
Clinical Nuclear Medicine|March 15, 2016
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CTChristina Bluemel, Markus Krebs, Bülent Polat, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2019
<sup>68</sup>Ga-PSMA I&T PET/CT for primary staging of prostate cancerWojciech Cytawa, Anna Katharina Seitz, Stefan Kircher, et al.
Theranostics|May 23, 2017
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative ApproachRudolf A Werner, Alexander Weich, Takahiro Higuchi, et al.
Neuro-Oncology|June 3, 2026
Spatial dissection of ADC/RPT targets defines heterogeneous expression landscapes and therapeutic implications in rhabdoid tumorsNic G Reitsam, Victoria E Fincke, Maria Daniela Hernandez Ramirez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2023
CXCR4-directed PET/CT with [<sup>68</sup> Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathologyNiklas Dreher, Stefanie Hahner, Carmina T Fuß, et al.
Molecular Imaging and Biology|July 18, 2018
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide TherapyRudolf A Werner, Harun Ilhan, Sebastian Lehner, et al.
The Oncologist|February 12, 2020
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System InvolvementMatteo Claudio Da Vià, Antonio Giovanni Solimando, Andoni Garitano-Trojaola, et al.
Pageof 27

Showing results (211-220 of 269) with videos related to

Sort By:
Pageof 27
Cancers|August 23, 2020
18F-FDG, 11C-Methionine, and 68Ga-Pentixafor PET/CT in Patients with Smoldering Multiple Myeloma: Imaging Pattern and Clinical FeaturesXiang Zhou, Alexander Dierks, Olivia Kertels, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 13, 2022
Diverse PSMA expression in primary prostate cancer: reason for negative [<sup>68</sup>Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimensWojciech Cytawa, Stefan Kircher, Hubert Kübler, et al.
Annals of Nuclear Medicine|August 16, 2018
Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implicationsRudolf A Werner, Ralph A Bundschuh, Lena Bundschuh, et al.
Clinical Nuclear Medicine|March 15, 2016
68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CTChristina Bluemel, Markus Krebs, Bülent Polat, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 19, 2019
<sup>68</sup>Ga-PSMA I&T PET/CT for primary staging of prostate cancerWojciech Cytawa, Anna Katharina Seitz, Stefan Kircher, et al.
Theranostics|May 23, 2017
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative ApproachRudolf A Werner, Alexander Weich, Takahiro Higuchi, et al.
Neuro-Oncology|June 3, 2026
Spatial dissection of ADC/RPT targets defines heterogeneous expression landscapes and therapeutic implications in rhabdoid tumorsNic G Reitsam, Victoria E Fincke, Maria Daniela Hernandez Ramirez, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 11, 2023
CXCR4-directed PET/CT with [<sup>68</sup> Ga]Ga-pentixafor in solid tumors-a comprehensive analysis of imaging findings and comparison with histopathologyNiklas Dreher, Stefanie Hahner, Carmina T Fuß, et al.
Molecular Imaging and Biology|July 18, 2018
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide TherapyRudolf A Werner, Harun Ilhan, Sebastian Lehner, et al.
The Oncologist|February 12, 2020
CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System InvolvementMatteo Claudio Da Vià, Antonio Giovanni Solimando, Andoni Garitano-Trojaola, et al.
Pageof 27